During the past decade, University General Hospital of Alexandroupolis conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 9 clinical trials were completed, i.e. on average, 21.4% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 8 clinical trials were completed. i.e. 32% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University General Hospital of Alexandroupolis" #1 sponsor was "Democritus University of Thrace" with 10 trials, followed by "Celgene" with 6 trials sponsored, "Boehringer Ingelheim" with 5 trials sponsored, "Hellenic Oncology Research Group" with 4 trials sponsored and "Amgen" with 4 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University General Hospital of Alexandroupolis" #1 collaborator was "University Hospital of Crete" with 2 trials as a collaborator, "University of Athens" with 2 trials as a collaborator, "A.O.U. Città della Salute e della Scienza - Molinette Hospital" with 1 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include 103 different institutions and companies that were collaborators in the rest 113 trials.

According to Clinical.Site data, the most researched conditions in "University General Hospital of Alexandroupolis" are "Cataract" (5 trials), "Breast Cancer" (4 trials), "Pulmonary Arterial Hypertension" (4 trials), "Atrial Fibrillation" (3 trials) and "Lung Diseases" (3 trials). Many other conditions were trialed in "University General Hospital of Alexandroupolis" in a lesser frequency.

Most popular intervention types in "University General Hospital of Alexandroupolis" are "Drug" (36 trials), "Other" (8 trials), "Diagnostic Test" (4 trials), "Procedure" (4 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Bevacizumab" (3 trials), "Dexamethasone" (3 trials), "Lenalidomide" (3 trials) and "Paclitaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "University General Hospital of Alexandroupolis" are 51 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University General Hospital of Alexandroupolis". undefined are not yet recruiting, 11 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 29 completed trials in University General Hospital of Alexandroupolis, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in University General Hospital of Alexandroupolis, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".